IntelGenx Technologies (IGXT)
(Delayed Data from OTC)
$0.16 USD
+0.01 (3.65%)
Updated May 13, 2024 03:18 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
IGXT 0.16 +0.01(3.65%)
Will IGXT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IGXT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for IGXT
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Shareholders Approve All Resolutions
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
IntelGenx Trials Novel Parkinson’s Treatment
IntelGenx doses first patients in Phase 2 'MONTPARK' trial